Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 25, Issue 1, Pages 117-127
Publisher
Informa Healthcare
Online
2015-11-21
DOI
10.1517/13543784.2016.1123248
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Omecamtiv Mecarbil Modulates the Kinetic and Motile Properties of Porcine β-Cardiac Myosin
- (2015) Yingying Liu et al. BIOCHEMISTRY
- Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase ActivityCLINICAL PERSPECTIVE
- (2015) Jens Petter Bakkehaug et al. Circulation-Heart Failure
- Omecamtiv Mecarbil, a Cardiac Myosin Activator, Increases Ca2+ Sensitivity in Myofilaments With a Dilated Cardiomyopathy Mutant Tropomyosin E54K
- (2015) Megan S. Utter et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Safety and Tolerability of Omecamtiv Mecarbil During Exercise in Patients With Ischemic Cardiomyopathy and Angina
- (2015) Barry H. Greenberg et al. JACC-Heart Failure
- Hypertrophic and Dilated Cardiomyopathy: Four Decades of Basic Research on Muscle Lead to Potential Therapeutic Approaches to These Devastating Genetic Diseases
- (2014) James A. Spudich BIOPHYSICAL JOURNAL
- Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure
- (2013) Milton Packer et al. JACC-Heart Failure
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
- (2012) et al. EUROPEAN JOURNAL OF HEART FAILURE
- Haemodynamic response during low-dose dobutamine infusion in patients with chronic systolic heart failure: comparison of echocardiographic and invasive measurements
- (2012) M. Egstrup et al. European Heart Journal-Cardiovascular Imaging
- Cardiac myosin activation part 1: From concept to clinic
- (2011) Fady I. Malik et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial
- (2011) John GF Cleland et al. LANCET
- Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
- (2011) John R Teerlink et al. LANCET
- Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
- (2011) F. I. Malik et al. SCIENCE
- Improvement of Cardiac Function by a Cardiac Myosin Activator in Conscious Dogs With Systolic Heart Failure
- (2010) You-Tang Shen et al. Circulation-Heart Failure
- Systolic Heart Failure
- (2010) John J.V. McMurray NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of Omecamtiv Mecarbil the First, Selective, Small Molecule Activator of Cardiac Myosin
- (2010) Bradley P. Morgan et al. ACS Medicinal Chemistry Letters
- A novel approach to improve cardiac performance: cardiac myosin activators
- (2009) John R. Teerlink HEART FAILURE REVIEWS
- Calcium Cycling and Signaling in Cardiac Myocytes
- (2007) Donald M. Bers Annual Review of Physiology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search